Literature DB >> 12542476

Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia.

Giovanni F Torelli1, Rossella Paolini, Caterina Tatarelli, Alessandra Soriani, Antonella Vitale, Anna Guarini, Angela Santoni, Robin Foa.   

Abstract

This study analysed the T-cell receptor (TCR)-CD3 zeta complex and the signal transduction apparatus of T-acute lymphoblastic leukaemia (T-ALL) blasts, and investigated the function of the ubiquitin-proteasome system. In all nine T-ALL samples studied, the leukaemic cells showed a marked reduction in the expression of the zeta chain, while a variety of tyrosine kinases (p56lck, ZAP70 and SYK) were normally present. There was no expression of the FcepsilonRIgamma chain. To confirm that this aberration was specific to immature T-ALL blasts, we investigated two patients with lymphoproliferative disorders of granular lymphocytes (LDGL), characterized by the expansion of mature T lymphocytes and found normal zeta chain expression. The reduction of the zeta chain protein was not reversible after 72 h stimulation with the anti-CD3 monoclonal antibody and interleukin 2, either alone or in combination. Northern blot analysis indicated that the reduced protein expression did not correspond to a defect at the mRNA level, nor were mutations in the coding region of the zeta chain found. We, therefore, hypothesized that the observed reduction of protein expression in T-ALL blasts could be secondary to an increased degradation at the proteasome level. Following selective inhibition of the proteasome, a marked increase of the zeta chain expression was observed. Moreover, an increase in the surface expression of CD3 was also documented. Taken together, these results indicate that the expression of the zeta subunit of the TCR-CD3 complex is consistently reduced in T-ALL blasts and that degradation of the protein is mediated by the proteasome system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12542476     DOI: 10.1046/j.1365-2141.2003.04044.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.

Authors:  Nobuyoshi Hanaoka; Bana Jabri; Zhenpeng Dai; Cezary Ciszewski; Anne M Stevens; Cassian Yee; Hideki Nakakuma; Thomas Spies; Veronika Groh
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Upregulated TCRζ enhances interleukin-2 production in T-cells from patients with CML.

Authors:  Xianfeng Zha; Shaohua Chen; Lijian Yang; Li Shi; Bo Li; Xiuli Wu; Yuhong Lu; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2012-10-11       Impact factor: 3.311

3.  ORP4L is essential for T-cell acute lymphoblastic leukemia cell survival.

Authors:  Wenbin Zhong; Qing Yi; Bing Xu; Shiqian Li; Tong Wang; Fupei Liu; Biying Zhu; Peter R Hoffmann; Guangju Ji; Pingsheng Lei; Guoping Li; Jiwei Li; Jian Li; Vesa M Olkkonen; Daoguang Yan
Journal:  Nat Commun       Date:  2016-09-01       Impact factor: 14.919

Review 4.  Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.

Authors:  Ewelina Grywalska; Marcin Pasiarski; Stanisław Góźdź; Jacek Roliński
Journal:  Onco Targets Ther       Date:  2018-10-04       Impact factor: 4.147

Review 5.  The role of the oncogenic Rab35 in cancer invasion, metastasis, and immune evasion, especially in leukemia.

Authors:  Fabian R Villagomez; Oscar Medina-Contreras; Jorge Francisco Cerna-Cortes; Genaro Patino-Lopez
Journal:  Small GTPases       Date:  2018-05-28

6.  New insights into antigen specific immunotherapy for chronic myeloid leukemia.

Authors:  Yangqiu Li; Chen Lin; Christian A Schmidt
Journal:  Cancer Cell Int       Date:  2012-12-15       Impact factor: 5.722

Review 7.  The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.

Authors:  Li Shi; Shaohua Chen; Lijian Yang; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2013-09-30       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.